- Home
- HLP vs BMEA Comparison
HLP vs BMEA Comparison
Compare HLP & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HLP
- BMEA
- Stock Information
- Founded
- HLP 2021
- BMEA 2017
- Country
- HLP China
- BMEA United States
- Employees
- HLP N/A
- BMEA N/A
- Industry
- HLP Industrial Machinery/Components
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- HLP Industrials
- BMEA Health Care
- Exchange
- HLP Nasdaq
- BMEA Nasdaq
- Market Cap
- HLP 66.1M
- BMEA 65.8M
- IPO Year
- HLP 2023
- BMEA 2021
- Fundamental
- Price
- HLP $0.93
- BMEA $1.81
- Analyst Decision
- HLP
- BMEA Strong Buy
- Analyst Count
- HLP 0
- BMEA 10
- Target Price
- HLP N/A
- BMEA $22.30
- AVG Volume (30 Days)
- HLP 178.0K
- BMEA 5.2M
- Earning Date
- HLP 07-01-2025
- BMEA 07-30-2025
- Dividend Yield
- HLP N/A
- BMEA N/A
- EPS Growth
- HLP N/A
- BMEA N/A
- EPS
- HLP N/A
- BMEA N/A
- Revenue
- HLP $14,105,620.00
- BMEA N/A
- Revenue This Year
- HLP N/A
- BMEA N/A
- Revenue Next Year
- HLP N/A
- BMEA N/A
- P/E Ratio
- HLP N/A
- BMEA N/A
- Revenue Growth
- HLP N/A
- BMEA N/A
- 52 Week Low
- HLP $0.72
- BMEA $1.29
- 52 Week High
- HLP $2.25
- BMEA $13.07
- Technical
- Relative Strength Index (RSI)
- HLP 44.59
- BMEA 44.35
- Support Level
- HLP $0.86
- BMEA $2.24
- Resistance Level
- HLP $0.96
- BMEA $3.08
- Average True Range (ATR)
- HLP 0.09
- BMEA 0.40
- MACD
- HLP 0.01
- BMEA -0.03
- Stochastic Oscillator
- HLP 65.34
- BMEA 25.07
About HLP Hongli Group Inc.
Hongli Group Inc is a cold roll-formed steel profile manufacturer in China. It customizes and manufactures cold roll-formed steel profiles for machinery and equipment in a variety of sectors, including but not limited to mining and excavation, construction, agriculture, and transportation. Geographically, the company generates the majority of its revenue from the PRC.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.